Leiomyosarcoma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
Following are some recently approved drugs in the treatment of the leimyosarcoma. | Following are some recently approved drugs in the treatment of the leimyosarcoma. | ||
* Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.<ref name="pmid25048043">Brodowicz T (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25048043 Trabectedin in soft tissue sarcomas.] ''Future Oncol'' 10 (8 Suppl):s1-5. [http://dx.doi.org/10.2217/fon.14.117 DOI:10.2217/fon.14.117] PMID: [https://pubmed.gov/25048043 25048043]</ref> | * [[Trabectedin]] was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.<ref name="pmid25048043">Brodowicz T (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25048043 Trabectedin in soft tissue sarcomas.] ''Future Oncol'' 10 (8 Suppl):s1-5. [http://dx.doi.org/10.2217/fon.14.117 DOI:10.2217/fon.14.117] PMID: [https://pubmed.gov/25048043 25048043]</ref> | ||
* Pazopanib, an oral therapy | * [[Pazopanib]], an oral therapy for advanced leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.<ref name="pmid22595799">van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. (2012) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=22595799 Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.] ''Lancet'' 379 (9829):1879-86. [http://dx.doi.org/10.1016/S0140-6736(12)60651-5 DOI:10.1016/S0140-6736(12)60651-5] PMID: [https://pubmed.gov/22595799 22595799]</ref> | ||
* Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work. | * Recently, [[Eribulin]] demonstrated an overall survival (OS) advantage in [[liposarcoma]] and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in soft tissue sarcoma is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. Eribulin works as a potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects.Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile.<ref name="pmid28621163">Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL (2017) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=28621163 Eribulin in advanced liposarcoma and leiomyosarcoma.] ''Expert Rev Anticancer Ther'' 17 (8):717-723. [http://dx.doi.org/10.1080/14737140.2017.1344098 DOI:10.1080/14737140.2017.1344098] PMID: [https://pubmed.gov/28621163 28621163]</ref><ref name="pmid28534249">Ratan R, Patel SR (2017) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=28534249 Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?] ''Curr Treat Options Oncol'' 18 (6):34. [http://dx.doi.org/10.1007/s11864-017-0477-x DOI:10.1007/s11864-017-0477-x] PMID: [https://pubmed.gov/28534249 28534249]</ref> | ||
* Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work.<ref name="pmid25795402">Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C et al. (2015) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25795402 Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.] ''Lancet Oncol'' 16 (4):457-64. [http://dx.doi.org/10.1016/S1470-2045(15)70070-7 DOI:10.1016/S1470-2045(15)70070-7] PMID: [https://pubmed.gov/25795402 25795402]</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:38, 7 July 2018
Following are some recently approved drugs in the treatment of the leimyosarcoma.
- Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.[1]
- Pazopanib, an oral therapy for advanced leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.[2]
- Recently, Eribulin demonstrated an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in soft tissue sarcoma is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. Eribulin works as a potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects.Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile.[3][4]
- Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work.[5]
References
- ↑ Brodowicz T (2014) Trabectedin in soft tissue sarcomas. Future Oncol 10 (8 Suppl):s1-5. DOI:10.2217/fon.14.117 PMID: 25048043
- ↑ van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829):1879-86. DOI:10.1016/S0140-6736(12)60651-5 PMID: 22595799
- ↑ Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL (2017) Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther 17 (8):717-723. DOI:10.1080/14737140.2017.1344098 PMID: 28621163
- ↑ Ratan R, Patel SR (2017) Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? Curr Treat Options Oncol 18 (6):34. DOI:10.1007/s11864-017-0477-x PMID: 28534249
- ↑ Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C et al. (2015) Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 16 (4):457-64. DOI:10.1016/S1470-2045(15)70070-7 PMID: 25795402